PR Newswire Clinical TrialsOriginal article
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
RegulatoryapprovedATR 1072Positive
AI Analysis
Summary
Atrium Therapeutics announced FDA clearance of the IND application for ATR 1072, a precision cardiology program for PRKAG2 Syndrome. The Corventis trial will be the first clinical study evaluating a potential treatment targeting the underlying cause of this rare genetic disorder.
Clinical Trial Data
Phase
Phase 1
Outcome Details
FDA Clearance of Investigational New Drug Application
Importance:6/10
Sentiment:
0.80
FDA clearanceIND approvalprecision cardiologyrare diseasePRKAG2 syndrome
Read the original article
Published by PR Newswire Clinical Trials on July 14, 2026 10:30 AM